Endocrine Abstracts

Background: Primary hyperparathyroidism (PHPT) is characterized by an excessive secretion of the parathyroid hormone (PTH) with normal or high calcium levels. The gold standard therapy involves minimally invasive parathyroidectomy with intraoperative PTH (ioPTH) monitoring. Different criteria have been identified when predicting cure rates using ioPTH values.Objective: To evaluate the percent ioPTH drop (ΔioPTH), the post-excision ioPTH, the first p...

Background: Stimulated Thyroglobulin levels measured at the time of remnant ablation (Htg-A) and BRAFV600E mutation were shown to have prognostic value in predicting persistent disease in DTC. The aim of this study was to evaluate the prognostic role of Htg-A combined with BRAFV600E status in association with revised American Thyroid Association (ATA) risk stratification.Patients and methods: 620 patients treated for a DTC were included in this study wit...

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...